Lawsuit Challenged Cartiva Synthetic Cartilage Implant
A new legal complaint alleges design defects in the recalled big toe implant used as an alternative to fusion surgery.
Updated on Sept. 30, 2026 in Arthritis
Live Poll
Do you trust medical device manufacturers to prioritize patient safety over product success rates?
A plaintiff has filed a product liability lawsuit against the manufacturers of the Cartiva synthetic cartilage implant following its 2024 recall. The case, filed in Kentucky, alleges that companies suppressed information regarding design defects and prone failures of the device.
Why it matters
This litigation highlights ongoing concerns regarding the safety and efficacy of the polyvinyl alcohol-based implant used for big toe joint pain. It serves as a reminder to patients to stay informed about medical device recalls and to discuss any persistent complications with their physician.
Official FDA assessments estimated the success rates for the implant at 21% to 46%, which significantly trailed the 87% success and 97% pain reduction rates originally claimed. The device, which received initial approval in 2016, was eventually pulled from the market due to these performance concerns.
The players
Cartiva Inc.
The medical device manufacturer that developed synthetic cartilage solutions for joint pain.
Wright Medical Technology Inc.
A medical device company specializing in orthopedic products including foot and ankle reconstruction technologies.
Stryker B.V.
A global medical technology firm that provides a wide range of orthopedic and surgical equipment.
Sandra K. Downey
The plaintiff who initiated the product liability complaint in federal court.
The details
The Cartiva device is a molded cylindrical implant designed to serve as an alternative to traditional big toe fusion surgery. Constructed from a polyvinyl alcohol-based gel, the implant was intended to replace damaged joint surfaces. The lawsuit alleges that manufacturers withheld knowledge of critical design flaws that made the device prone to failure after implantation.
Timeline
The Cartiva implant received initial FDA approval in 2016.
The FDA recalled the synthetic cartilage implant in October 2024.
Sandra K. Downey filed the product liability lawsuit on September 23, 2026.
Health Landscape
This litigation underscores the intense scrutiny currently applied to orthopedic devices that promise alternatives to traditional fusion surgery. It sits within a larger trend of increased monitoring for implantable devices that may not deliver the long-term clinical benefits suggested during initial approval.
Patients who previously received a Cartiva implant should speak with their physician about any new or ongoing toe pain. It is important to confirm with your clinical team whether any follow-up imaging or evaluation is necessary given the device's recall status.
The takeaway
The Cartiva recall serves as a critical example of the importance of questioning the long-term performance claims of new medical devices. If you have undergone joint procedures, maintain an open dialogue with your physician to monitor for unexpected symptoms or signs of device failure.
Further reading
For more information on the management of joint conditions and surgical options, visit our guide on Arthritis.
Source note: This article includes information reported by AboutLawsuits.
Live Poll
Do you trust medical device manufacturers to prioritize patient safety over product success rates?
